

30th October, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza, G. Block, Bandra Kurla
Complex, Bandra (East),
Mumbai - 400 051

Script Code: 500259

Script Code: LYKALABS

Sub: Submission of Press Release on Unaudited Financial Results for the Second Quarter ended September 30, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release being issued by the Company today, regarding the Unaudited Financial Results of the Company for the second quarter ended September 30, 2026.

The Board of Directors at its meeting held today, i.e., October 30, 2026, has inter-alia approved the said financial results.

The above information will also be made available on the website of the Company at www.lykalabs.com

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,
For **Lyka Labs Limited**

SHAIENDR Digitally signed by
A KUMAR SHAIENDRA
AGRAWAL KUMAR AGRAWAL
Date: 2026.10.30
17:32:53 +05'30'

Shailendra Agrawal
Company Secretary and Compliance Officer
Encl.: as above

Press Release: Lyka Labs Limited Q2FY27 & H1FY27

Mumbai, October 30, 2026 : Lyka Labs Limited today announced its unaudited financial results for the second quarter and half year ended 30th September 2026 of the financial year 2026-27

Key Financials of Q2 FY27

- Standalone Revenue from Operations up 34.06% at Rs. 4,419.95 Lacs.
- Consolidated Revenue from Operations up 20.56% at Rs. 4,419.95 Lacs.
- Standalone EBITDA margin @ 9.49% in Q2 FY27 as against (5.63)% in Q2 FY26
- Consolidated EBITDA margin @ 9.37% in Q2 FY27 as against (3.95)% in Q2 FY26
- Standalone Net Profit up 136.32 % at Rs. 131.50 Lacs as against Rs. (362.07) Lacs
- Consolidated Net Profit up 139.54 % at Rs. 127.11 Lacs as against Rs. (321.44) Lacs

						(Rs. In lacs)
	Standalone			Consolidated		
Particulars	Q2 FY27	Q2 FY26	Growth	Q2 FY27	Q2 FY26	Growth
Revenue from Operations	4,419.95	3,297.03	34.06%	4,419.95	3,666.05	20.56%
EBITDA	419.31	-185.52	326.02%	414.21	-144.67	386.31%
Finance Cost	102.18	78.58		102.18	78.87	
Profit Before Tax	111.76	-479.05	123.33%	106.66	-438.49	124.32%
Net Profit After Tax	131.50	-362.07	136.32%	127.11	-321.44	139.54%

Key Financials of H1 FY27

- Standalone Revenue from Operations up 39.20% at Rs. 8,650.89 Lacs.
- Consolidated Revenue from Operations up 24.14% at Rs. 8,650.89 Lacs.
- Standalone EBITDA margin @ 10.64% in HY FY27 as against 3.66% in HY FY26
- Consolidated EBITDA margin @ 10.53% in HY FY27 as against 4.12% in HY FY26
- Standalone Net Profit up 221.55% at Rs. 341.53 Lacs as against Rs. (280.99) Lacs
- Consolidated Net Profit up 249.57 % at Rs. 331.77 Lacs as against Rs. (221.81) Lacs

						(Rs. In lacs)
	Standalone			Consolidated		
Particulars	H1 FY27	H2 FY26	Growth	H2 FY27	H2 FY26	Growth
Revenue from Operations	8,650.89	6,214.67	39.20%	8,650.89	6,968.59	24.14%
EBITDA	920.44	227.55	304.50%	910.80	287.07	217.27%
Finance Cost	203.00	163.72		203.00	164.25	
Profit Before Tax	311.10	-362.31	185.87%	301.46	-303.31	199.39%
Net Profit After Tax	341.53	-280.99	221.55%	331.77	-221.81	249.57%



Revenue Analysis:

- Q2FY27 Domestic Revenue up 12.89% at Rs. 2,948.90 Lacs
- H1FY27 Domestic Revenue up 14.30% at Rs. 5,601.01 Lacs.
- Q2FY27 Export Revenue up 51.89% at Rs. 1,415.49 Lacs.
- H1FY27 Export Revenue up 59.74% at Rs. 2,898.92 Lacs.

Revenue Break-up						(Rs. In lacs)
Particulars	Q2 FY27	Q2 FY26	Growth	H1FY27	H1FY26	Growth
Domestic						
Branded Formulation	521.43	505.38	3.18%	1,259.10	959.96	31.16%
Branded Veterinary	824.82	557.19	48.03%	1,412.17	854.09	65.34%
P2P	1,602.65	1,549.52	3.43%	2,929.75	3,086.21	-5.07%
Total Domestic Sales	2,948.90	2,612.10	12.89%	5,601.01	4,900.26	14.30%
Exports						
Branded Formulation	1,415.49	931.93	51.89%	2,898.92	1,814.79	59.74%
Total Export Sales	1,415.49	931.93	51.89%	2,898.92	1,814.79	59.74%
Other Operating Income	55.55	122.02	-54.47%	150.96	253.54	-40.46%
Consolidated Revenue	4,419.95	3,666.05	20.56%	8,650.89	6,968.59	24.14%

About Lyka Labs Limited:

Lyka Labs Limited is engaged in the manufacturing and marketing of finished pharmaceutical formulations for human and animal healthcare across a wide range of therapeutic segments, catering to both domestic and international markets.



Shailendra Kumar Agarwal
Company Secretary
Email : companysecretary@lykalabs.com

